Stempoint Capital LP
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Stempoint Capital LP reported 76 stock positions worth $495.9 million. Its top holding was Roivant Sciences (ROIV) at 12.8% of the portfolio, followed by Uniqure (QURE, 6.1%) and Scholar Rock (SRRK, 5.5%). Compared with Q2 2025, it opened 39 new positions, sold out of 13, added to 18 and reduced 17. The biggest buy was Roivant Sciences (ROIV, shares +597%) and the biggest sale an exit from Merus (MRUS).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001952142
- Portfolio Value
- $495.9M (Q3 2025)
- SEC Filing
- 0001420506-25-003308 ↗ filed Nov 14, 2025
Holdings Value
Holdings 76 stocks · $495.9M
| ROIV Roivant Sciences Ltd. | 12.81% | 4,197,187 | $63.5M | Add +597.5% |
| QURE Uniqure NV | 6.15% | 522,155 | $30.5M | Reduce -8.8% |
| SRRK Scholar Rock Holding Corp. | 5.45% | 726,204 | $27.0M | Add +37.5% |
| IMVT Immunovant Inc. | 5.17% | 1,589,580 | $25.6M | Add +22.2% |
| DNLI Denali Therapeutics Inc. | 5.08% | 1,734,659 | $25.2M | Add +145.0% |
| SNDX Syndax Pharmaceuticals Inc. | 4.24% | 1,366,205 | $21.0M | Reduce -42.4% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.20% | 655,385 | $15.9M | Reduce -48.2% |
| WVE Wave Life Sciences Ltd. | 3.11% | 2,110,152 | $15.4M | Add +134.4% |
| BHVN Biohaven Ltd. | 3.08% | 1,017,311 | $15.3M | Add +482.1% |
| CDTX Cidara Therapeutics Inc. | 2.94% | 152,325 | $14.6M | Reduce -42.9% |
| ABVX Abivax SA-ADR | 2.85% | 166,273 | $14.1M | Add +89.5% |
| IDYA Ideaya Biosciences Inc. | 2.04% | 371,825 | $10.1M | Add +124.2% |
| RYTM Rhythm Pharmaceuticals Inc. | 1.86% | 91,444 | $9.2M | Reduce -48.3% |
| ARGX Argenx SE - ADR | 1.85% | 12,465 | $9.2M | New |
| SRZN Surrozen Inc. | 1.85% | 713,463 | $9.2M | Add +3.9% |
| RVMD Revolution Medicines Inc. | 1.75% | 185,380 | $8.7M | New |
| RZLT Rezolute Inc. | 1.74% | 917,630 | $8.6M | Add +42.3% |
| GHRS GH Research PLC | 1.57% | 545,275 | $7.8M | Add +440.8% |
| ARQT Arcutis Biotherapeutics Inc. | 1.57% | 411,893 | $7.8M | Add +100.3% |
| VTGN Vistagen Therapeutics Inc. | 1.56% | 2,488,685 | $7.7M | Add +3.1% |
| XENE Xenon Pharmaceuticals Inc. | 1.56% | 192,295 | $7.7M | New |
| ALKS Alkermes PLC | 1.46% | 241,637 | $7.2M | Reduce -31.2% |
| CELC Celcuity Inc. | 1.36% | 136,710 | $6.8M | New |
| BBIO Bridgebio Pharma Inc. | 1.33% | 127,435 | $6.6M | Add +133.3% |
| INSM Insmed Inc. | 1.26% | 43,419 | $6.3M | Reduce -29.5% |
| DYN Dyne Therapeutics Inc. | 1.21% | 474,612 | $6.0M | New |
| MLYS Mineralys Therapeutics Inc. | 1.21% | 158,112 | $6.0M | Reduce -75.0% |
| AKRO Akero Therapeutics Inc. | 1.16% | 121,410 | $5.8M | Add +4.0% |
| JAZZ Jazz Pharmaceuticals PLC | 1.04% | 39,072 | $5.1M | New |
| RNAM Avidity Biosciences Inc. | 1.00% | 114,053 | $5.0M | New |
| NAMS Newamsterdam Pharma Co. NV | 0.86% | 150,573 | $4.3M | Reduce -1.4% |
| OCUL Ocular Therapeutix Inc. | 0.85% | 359,470 | $4.2M | New |
| MDGL Madrigal Pharmaceuticals Inc. | 0.76% | 8,207 | $3.8M | Reduce -84.4% |
| AMLX Amylyx Pharmaceuticals Inc. | 0.76% | 276,884 | $3.8M | New |
| INCY Incyte Corp. | 0.75% | 43,754 | $3.7M | New |
| GPCR Structure Therapeutics Inc. | 0.73% | 129,335 | $3.6M | New |
| TRVI Trevi Therapeutics Inc. | 0.65% | 350,710 | $3.2M | New |
| PTGX Protagonist Therapeutics Inc. | 0.64% | 47,954 | $3.2M | Add +185.9% |
| NKTR Nektar Therapeutics | 0.61% | 53,201 | $3.0M | New |
| ASND Ascendis Pharma A/S | 0.61% | 15,149 | $3.0M | New |
| TECX Tectonic Therapeutic Inc. | 0.60% | 188,999 | $3.0M | Add +372.5% |
| HROW Harrow Inc. | 0.56% | 57,619 | $2.8M | New |
| TSHA Taysha Gene Therapies Inc. | 0.55% | 839,669 | $2.7M | Reduce -30.3% |
| EQ Equillium Inc. | 0.55% | 1,908,935 | $2.7M | New |
| UTHR United Therapeutics Corp. | 0.53% | 6,264 | $2.6M | New |
| CGON CG Oncology Inc. | 0.51% | 63,019 | $2.5M | New |
| QQQ Invesco QQQ Trust Series 1 | 0.46% | 3,797 | $2.3M | New |
| BBOT Bridgebio Oncology Therapeut | 0.44% | 186,614 | $2.2M | New |
| TNGX Tango Therapeutics Inc. | 0.42% | 245,378 | $2.1M | Add +17.5% |
| ORIC Oric Pharmaceuticals Inc. | 0.40% | 166,461 | $2.0M | Reduce -17.1% |
| XFOR X4 Pharmaceuticals Inc. | 0.38% | 555,411 | $1.9M | New |
| PEPG Pepgen Inc. | 0.36% | 389,189 | $1.8M | New |
| ASMB Assembly Biosciences Inc. | 0.34% | 66,130 | $1.7M | New |
| DNTH Dianthus Therapeutics Inc. | 0.33% | 41,382 | $1.6M | New |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.32% | 150,000 | $1.6M | No change |
| TARA Protara Therapeutic Inc. | 0.32% | 363,666 | $1.6M | Reduce -68.2% |
| CMPS Compass Pathways PLC | 0.32% | 275,620 | $1.6M | New |
| PYXS Pyxis Oncology Inc. | 0.31% | 689,538 | $1.5M | New |
| MBX MBX Biosciences Inc. | 0.26% | 75,000 | $1.3M | Reduce -46.8% |
| ADCT Adc Therapeutics SA | 0.23% | 283,286 | $1.1M | No change |
| ACLX Arcellx Inc. | 0.19% | 11,376 | $934K | Reduce -94.3% |
| ABUS Arbutus Biopharma Corp. | 0.19% | 205,388 | $932K | New |
| MIND MEDICINE MINDMED INC | 0.18% | 76,875 | $906K | Reduce -15.4% |
| ENTA Enanta Pharmaceuticals Inc. | 0.18% | 75,194 | $900K | New |
| ZBIO Zenas Biopharma Inc. | 0.17% | 38,742 | $860K | New |
| WHWK Whitehawk Therapeutics Inc. | 0.16% | 424,082 | $806K | New |
| CRVS Corvus Pharmaceuticals Inc. | 0.14% | 96,439 | $711K | New |
| KALV Kalvista Pharmaceuticals Inc. | 0.14% | 56,770 | $691K | Reduce -85.3% |
| MGTX Meiragtx Holdings PLC | 0.14% | 81,858 | $674K | New |
| TERN Terns Pharmaceuticals Inc. | 0.14% | 89,617 | $673K | New |
| ARCT Arcturus Therapeutics Holdin | 0.13% | 35,606 | $656K | New |
| VTYX Ventyx Biosciences Inc. | 0.10% | 167,470 | $521K | New |
| ATAIBECKLEY INC filed as ATAI LIFE SCIENCES NV | 0.08% | 76,032 | $402K | New |
| CLPT Clearpoint Neuro Inc. | 0.07% | 16,651 | $363K | New |
| IVVD Invivyd Inc. | 0.06% | 278,608 | $306K | New |
| IVA Inventiva SA - ADR | 0.04% | 30,824 | $178K | New |
Options reported separately and not counted above: BHVN calls ($1.2M), CNTA calls ($906K), XBI puts ($725K), IONS calls ($138K), CRSP calls ($59K), SNDX calls ($55K), IMVT calls ($50K), ARKG calls ($30K), SRRK calls ($24K), AKRO puts ($10K), ABUS calls ($10K).
Portfolio Sells Q2 2025 → Q3 2025
| MRUS Merus NV | Sold out | 0.00% | −4.51 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -84.4% | 0.76% | −4.38 |
| ACLX Arcellx Inc. | Reduce -94.3% | 0.19% | −4.08 |
| LEGN Legend Biotech Corp.-ADR | Sold out | 0.00% | −3.09 |
| GERN Geron Corp. | Sold out | 0.00% | −3.02 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -42.4% | 4.24% | −2.92 |
| ZLAB Zai Lab Ltd.-ADR | Sold out | 0.00% | −2.82 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -48.2% | 3.20% | −2.15 |
| ALKS Alkermes PLC | Reduce -31.2% | 1.46% | −1.77 |
| LENZ Lenz Therapeutics Inc. | Sold out | 0.00% | −1.74 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -48.3% | 1.86% | −1.73 |
| MLYS Mineralys Therapeutics Inc. | Reduce -75.0% | 1.21% | −1.54 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −1.47 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -85.3% | 0.14% | −1.27 |
| CDTX Cidara Therapeutics Inc. | Reduce -42.9% | 2.94% | −1.24 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −1.18 |
| BBOT Bridgebio Oncology Therapeut | Sold out | 0.00% | −1.06 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −1.00 |
| TARA Protara Therapeutic Inc. | Reduce -68.2% | 0.32% | −0.80 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −0.79 |
| INSM Insmed Inc. | Reduce -29.5% | 1.26% | −0.73 |
| JANX Janux Therapeutics Inc. | Sold out | 0.00% | −0.67 |
| PRAX Praxis Precision Medicines I | Sold out | 0.00% | −0.44 |
| TSHA Taysha Gene Therapies Inc. | Reduce -30.3% | 0.55% | −0.34 |
| MBX MBX Biosciences Inc. | Reduce -46.8% | 0.26% | −0.25 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -17.1% | 0.40% | −0.25 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −0.23 |
| NAMS Newamsterdam Pharma Co. NV | Reduce -1.4% | 0.86% | −0.03 |
| MIND MEDICINE MINDMED INC | Reduce -15.4% | 0.18% | −0.01 |
| QURE Uniqure NV | Reduce -8.8% | 6.15% | +3.58 |
Portfolio Buys Q2 2025 → Q3 2025
| ROIV Roivant Sciences Ltd. | Add +597.5% | 12.81% | +10.62 |
| ABVX Abivax SA-ADR | Add +89.5% | 2.85% | +2.63 |
| BHVN Biohaven Ltd. | Add +482.1% | 3.08% | +2.29 |
| DNLI Denali Therapeutics Inc. | Add +145.0% | 5.08% | +1.89 |
| ARGX Argenx SE - ADR | New | 1.85% | +1.85 |
| RVMD Revolution Medicines Inc. | New | 1.75% | +1.75 |
| XENE Xenon Pharmaceuticals Inc. | New | 1.56% | +1.56 |
| CELC Celcuity Inc. | New | 1.36% | +1.36 |
| WVE Wave Life Sciences Ltd. | Add +134.4% | 3.11% | +1.23 |
| DYN Dyne Therapeutics Inc. | New | 1.21% | +1.21 |
| GHRS GH Research PLC | Add +440.8% | 1.57% | +1.18 |
| JAZZ Jazz Pharmaceuticals PLC | New | 1.04% | +1.04 |
| RNAM Avidity Biosciences Inc. | New | 1.00% | +1.00 |
| IDYA Ideaya Biosciences Inc. | Add +124.2% | 2.04% | +0.92 |
| OCUL Ocular Therapeutix Inc. | New | 0.85% | +0.85 |
| RZLT Rezolute Inc. | Add +42.3% | 1.74% | +0.81 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 0.76% | +0.76 |
| INCY Incyte Corp. | New | 0.75% | +0.75 |
| GPCR Structure Therapeutics Inc. | New | 0.73% | +0.73 |
| TRVI Trevi Therapeutics Inc. | New | 0.65% | +0.65 |
| ARQT Arcutis Biotherapeutics Inc. | Add +100.3% | 1.57% | +0.64 |
| NKTR Nektar Therapeutics | New | 0.61% | +0.61 |
| ASND Ascendis Pharma A/S | New | 0.61% | +0.61 |
| BBIO Bridgebio Pharma Inc. | Add +133.3% | 1.33% | +0.58 |
| HROW Harrow Inc. | New | 0.56% | +0.56 |
| EQ Equillium Inc. | New | 0.55% | +0.55 |
| UTHR United Therapeutics Corp. | New | 0.53% | +0.53 |
| CGON CG Oncology Inc. | New | 0.51% | +0.51 |
| QQQ Invesco QQQ Trust Series 1 | New | 0.46% | +0.46 |
| BBOT Bridgebio Oncology Therapeut | New | 0.44% | +0.44 |
| XFOR X4 Pharmaceuticals Inc. | New | 0.38% | +0.38 |
| PEPG Pepgen Inc. | New | 0.36% | +0.36 |
| PTGX Protagonist Therapeutics Inc. | Add +185.9% | 0.64% | +0.34 |
| TECX Tectonic Therapeutic Inc. | Add +372.5% | 0.60% | +0.34 |
| ASMB Assembly Biosciences Inc. | New | 0.34% | +0.34 |
| DNTH Dianthus Therapeutics Inc. | New | 0.33% | +0.33 |
| CMPS Compass Pathways PLC | New | 0.32% | +0.32 |
| PYXS Pyxis Oncology Inc. | New | 0.31% | +0.31 |
| VTGN Vistagen Therapeutics Inc. | Add +3.1% | 1.56% | +0.24 |
| ABUS Arbutus Biopharma Corp. | New | 0.19% | +0.19 |
| ENTA Enanta Pharmaceuticals Inc. | New | 0.18% | +0.18 |
| ZBIO Zenas Biopharma Inc. | New | 0.17% | +0.17 |
| WHWK Whitehawk Therapeutics Inc. | New | 0.16% | +0.16 |
| CRVS Corvus Pharmaceuticals Inc. | New | 0.14% | +0.14 |
| MGTX Meiragtx Holdings PLC | New | 0.14% | +0.14 |
| TERN Terns Pharmaceuticals Inc. | New | 0.14% | +0.14 |
| ARCT Arcturus Therapeutics Holdin | New | 0.13% | +0.13 |
| VTYX Ventyx Biosciences Inc. | New | 0.10% | +0.10 |
| ATAIBECKLEY INC | New | 0.08% | +0.08 |
| CLPT Clearpoint Neuro Inc. | New | 0.07% | +0.07 |
Options Activity Q2 2025 → Q3 2025
| BHVN Biohaven Ltd. | call | New | 480,000 | $1.2M |
| CNTA Centessa Pharmaceuticals Ltd. | call | New | 172,500 | $906K |
| XBI SS SPDR S&P Biotech ETF | put | New | 1,490,100 | $725K |
| ROIV Roivant Sciences Ltd. | call | Sold out | 915,000 | $618Kbefore exit |
| IONS Ionis Pharmaceuticals Inc. | call | New | 50,000 | $138K |
| CRSP Crispr Therapeutics AG | call | New | 40,000 | $59K |
| SNDX Syndax Pharmaceuticals Inc. | call | New | 100,000 | $55K |
| GERN Geron Corp. | call | Sold out | 300,000 | $53Kbefore exit |
| IMVT Immunovant Inc. | call | Add +150.0% | 250,000 | $50K |
| ARKG ARK Genomic Revolution ETF | call | New | 200,000 | $30K |
| SRRK Scholar Rock Holding Corp. | call | New | 18,400 | $24K |
| AKRO Akero Therapeutics Inc. | put | New | 15,500 | $10K |
| ABUS Arbutus Biopharma Corp. | call | New | 95,000 | $10K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 73 | $577.9M | TNGX, ABVX, RVMD, ERAS, TYRA |
| Q1 2026Amended | 70 | $520.3M | SRRK, ABVX, SNDX, RVMD, IMVT |
| Q4 2025 | 75 | $582.7M | ABVX, SRRK, CNTA, SNDX, GPCR |
| Q3 2025 | 76 | $495.9M | ROIV, QURE, SRRK, IMVT, DNLI |
| Q2 2025 | 50 | $310.6M | SNDX, IMVT, SRRK, CNTA, MDGL |
| Q1 2025 | 52 | $313.1M | ROIV, SNDX, SRRK, ACLX, MRUS |
| Q4 2024 | 48 | $398.7M | SNDX, ROIV, IMVT, MRUS, CRNX |
| Q3 2024 | 50 | $333.4M | SNDX, ROIV, MRUS, IMVT, ARQT |
| Q2 2024Amended | 42 | $339.9M | SNDX, ROIV, IMVT, CRNX, MRUS |
| Q1 2024Amended | 45 | $374.3M | ROIV, CRNX, SNDX, ARQT, IMVT |